US Capitol Capsule: Fights Over Interpretation Of Biosimilars Law: Disruption To Market's Future?
This article was originally published in Scrip
Executive Summary
With some of the most complicated questions not likely to be resolved by the courts for potentially three to five years over the interpretation of various provisions in the extremely complex US biosimilars law – and the likelihood many more disputes will arise for years to come beyond the expected patent litigation – will some firms hold back or even avoid the area altogether, leading to the American market not being as robust as it could be?